

Osmolex ER[™] (amantadine) – New drug approval

- On February 19, 2018, <u>Osmotica Pharmaceutical announced</u> the FDA approval of <u>Osmolex ER</u> (<u>amantadine</u>), for the treatment of Parkinson's disease and for the treatment of drug-induced extrapyramidal reactions in adult patients.
- Amantadine is also available generically as immediate-release <u>capsules</u>, <u>tablets</u>, and <u>oral solution</u>, and as extended-release capsules (Gocovri[™]).
 - Amantadine capsules, tablets and oral solution are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
 Amantadine is also indicated in the treatment of Parkinson's disease/syndrome and druginduced extrapyramidal reactions.
 - Gocovri is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
- Osmolex ER tablets contain amantadine in an extended-release core and an outer immediaterelease layer that allows for release of amantadine throughout the day.
- The efficacy of Osmolex ER is based upon bioavailability studies comparing Osmolex ER to immediate-release amantadine.
- Osmolex ER is contraindicated in patients with end-stage renal disease (ie, creatinine clearance below 15 mL/min/1.73 m²).
- Warnings and precautions of Osmolex ER include falling asleep during activities of daily living and somnolence, suicidality and depression, hallucinations/psychotic behavior, dizziness and orthostatic hypotension, withdrawal-emergent hyperpyrexia and confusion, and impulse control/compulsive behaviors.
- The most common adverse reactions (≥ 5%) with immediate-release amantadine use were nausea, dizziness/lightheadedness, and insomnia.
- The recommended initial dosage of Osmolex ER is 129 mg orally once daily in the morning.
 - The dosage may be increased in weekly intervals to a maximum daily dose of 322 mg (administered as a 129 mg and 193 mg tablet), taken in the morning.
 - Osmolex ER is not interchangeable with other amantadine immediate- or extended-release products.
 - For patients unable to tolerate > 100 mg/day of immediate-release amantadine, there is no equivalent dose or dosing regimen of Osmolex ER.
- Osmotica Pharmaceutical's launch plans for Osmolex ER are pending. Osmolex ER will be available as 129 mg, 193 mg, and 258 mg extended-release tablets.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.